SCHEMBL4236352

SCHEMBL4236352

FC(F)(F)c1ccc(Cl)c(CN2CCCC2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
KDM4E B2RXH2 3/20 0.58
GAA P10253 1/20 0.53
MAOA P21397 1/20 0.52
MEN1 O00255 1/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.49
ATM Q13315 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CACNA1B Q00975 1/20 0.47
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TRAP1 Q12931 1/20 0.45
MAOB P27338 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
CHKA P35790 1/20 0.43
OPRM1 P35372 1/20 0.43
OPRL1 P41146 1/20 0.43
FPR3 P25089 1/20 0.43
FPR2 P25090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4235827 0.98 ALDH1A1 (0.61) ALDH1A1KDM4EGAAMAOAMEN1
SCHEMBL4242830 0.86 CYP2A13 (0.56) ALDH1A1KDM4EMAOAL3MBTL1POLB
SCHEMBL17428664 0.84 DCUN1D1 (0.46) ALDH1A1KDM4ETSHRKMT2ATRAP1
SCHEMBL19083727 0.83 OPRL1 (0.46) ALDH1A1KDM4EMAOATRAP1MAOB
SCHEMBL22365226 0.82 KDM4E (0.56) ALDH1A1KDM4EGAAMAOAKMT2A
SCHEMBL20697775 0.82 OPRL1 (0.46) ALDH1A1KDM4EGAAMAOAPOLB
SCHEMBL22365231 0.81 KDM4E (0.58) ALDH1A1KDM4EGAAMAOAKMT2A
SCHEMBL19075619 0.81 SLC6A2 (0.47) ALDH1A1KDM4ETRAP1MAOBOPRM1
SCHEMBL19083729 0.80 OPRL1 (0.46) ALDH1A1KDM4EGAAL3MBTL1POLB
SCHEMBL4621258 0.79 KDM4E (0.57) ALDH1A1KDM4EGAAMAOATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAYZME PHARMACEUTICALS LTD. (CA) 2009-05-28 US disclosed
EP-1871357-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE Inflazyme Pharmaceuticals, Ltd. (CA) 2008-01-02 EP disclosed
WO-2006108149-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAZYME PHARMACEUTICALS LTD. (CA) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE CYP2A6, CYP2B6, CYP2D6 ALDH1A1 77/4885KDM4E 866/4885GAA 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.